Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.47Last Year’s EPS
0.3Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced several strong operational and financial achievements — including the Melinta acquisition, realization of $35M synergies, robust pro forma revenue ($401.3M), healthy cash (~$148.5M) and a clear pipeline catalyst with RIZEAO top-line data expected in Q2 2026 — against meaningful near-term headwinds tied to the TDAPA-to-bundle reimbursement transition, expected price erosion for DEFENCATH, customer concentration risk, and materially higher operating expenses following the merger. Management offered conservative guidance that reflects those reimbursement risks while preserving upside potential from Medicare Advantage contracting, inpatient adoption, and RIZEAO/TPN development programs. On balance, the positives around completed integration, liquidity, and upcoming clinical catalysts are offset by significant reimbursement and concentration risks that could materially pressure DEFENCATH revenue absent favorable contracting or legislative outcomes.Company Guidance
Record Annual DEFENCATH Sales
DEFENCATH generated $258.8 million in net sales for 2025 (reported as "just under $260,000,000"), representing the company's largest single-product revenue contribution for the year.
Acquisition of Melinta and Achieved Synergies
Closed acquisition of Melinta Therapeutics (08/29/2025) and realized targeted annual synergies of $35,000,000 during 2025; Melinta contributed $37.4 million to Q4 2025 revenue.
Strong Quarterly and Pro Forma Revenue
Q4 2025 revenue was $128.6 million (DEFENCATH $91.2M; Melinta $37.4M). Pro forma full-year 2025 revenue (combined CorMedix + Melinta) was $401.3 million, in line with prior guidance.
Affirmed 2026 and 2027 Financial Guidance
Affirmed 2026 DEFENCATH guidance of $150M–$170M and 2027 DEFENCATH guidance of $100M–$125M. Company also affirmed full-year 2026 consolidated revenue guidance of $300M–$320M and adjusted EBITDA of $100M–$125M.
Strong Adjusted EBITDA and Net Income
Q4 adjusted EBITDA was $77.2 million (within guidance). CorMedix recognized net income of $14.0 million for 2025 and pre-tax Q4 income of $56.4 million (an increase of $43.0M vs. 2024).
Healthy Liquidity and Operating Cash Flow
Ended Q4 with $148.5 million in cash, cash equivalents, and short-term investments; operating cash flow in the quarter was nearly $100 million.
Clinical Milestones and Pipeline Value
Phase III RESPECT (RIZEAO prophylaxis) completed enrollment September 2025 with database lock expected March 2026 and top-line data anticipated in Q2 2026. Company estimates RIZEAO market opportunity at ~$2.5 billion across indications and DEFENCATH in TPN at $500M–$750M.
Progress on DEFENCATH TPN Program and NEUTROGUARD Enrollment
Phase III NEUTROGUARD (DEFENCATH for CLABSI prevention in TPN patients) is ~30% enrolled toward the minimum target of 90 patients; study completion anticipated in early 2027.
Workforce and Integration Progress
Headcount increased from ~100 to just under 200 employees post-merger (approximately 100% growth), reflecting integration and scaling to support commercial expansion. Management also initiated an active share repurchase program.
CRMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 05, 2026 | $7.12 | $6.30 | -11.52% |
Nov 12, 2025 | $11.19 | $11.42 | +2.06% |
Aug 07, 2025 | $11.95 | $10.81 | -9.54% |
May 06, 2025 | $9.03 | $11.16 | +23.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cormedix (CRMD) report earnings?
Cormedix (CRMD) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Cormedix (CRMD) earnings time?
Cormedix (CRMD) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRMD EPS forecast?
CRMD EPS forecast for the fiscal quarter 2026 (Q1) is 0.47.